FB 849
Alternative Names: FB-849Latest Information Update: 13 Jun 2024
At a glance
- Originator 1St Biotherapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Hematopoietic progenitor kinase 1 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
- Phase I Cancer
Most Recent Events
- 05 Apr 2024 Pharmacodynamics data from a preclinical studies in Cancer presented at the 115th Annual Meeting of the American Association for Cancer Research, 2024 (AACR-2024)
- 09 Oct 2023 Phase-I/II clinical trials in Solid tumours (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (PO) (NCT05761223)
- 09 Oct 2023 Phase-I/II clinical trials in Solid tumours (Monotherapy, Late-stage disease, Second-line therapy or greater) in USA (PO) (NCT05761223)